Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse

A study of 64 patients

Koichi Miyamura, Tohru Tahara, Mitsune Tanimoto, Yoshihisa Morishita, Kouhei Kawashima, Yasuo Morishima, Hidehiko Saito, Shinobu Tsuzuki, Kunihiko Takeyama, Yoshihisa Kodera, Kohji Matsuyama, Noriyuki Hirabayashi, Hironori Yamada, Kazuyuki Naito, Kuniyuki Imai, Hisashi Sakamaki, Osamu Asai, Shuki Mizutani

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

We report here the results of polymerase chain reaction (PCR) for bcr-abl transcript and clinical details derived from 64 chronic myelogenous leukemia (CML) patients after allogeneic bone marrow transplantation (BMT). A total of 139 samples (2 to 220 weeks after BMT) were analyzed and bcr-abl transcript was detected in 99 samples from 52 patients. Patients were defined as bcr-abl early negative (EN) if they had ≥1 negative PCR result ≤1 year post-BMT (n = 13), and bcr-abl late positive (LP) if they had ≥1 positive PCR result ≥1 year post-BMT (n = 21). Among LP patients, only two patients had hematologic/cytogenetic (clinical) relapse. Another 19 LP patients remained in clinical remission 7 to 130 weeks after positive analysis for bcr-abl transcript, including 5 patients who had persistent bcr-abl transcript detectable even 2 years after BMT. To estimate the relationship between clinical data and residual bcr-abl transcript, EN patients are compared with LP patients. However, no clinical data studied were significantly associated with the persistent PCR positivity. If only patients in chronic phase are compared, the t-test showed significant correlation between leukocyte count just before BMT and sustained bcr-abl transcript (P <.05). These results suggest that PCR positivity is frequently observed in CML patients who sustain clinical remission after BMT, without being predictive of imminent clinical relapse. Tumor burden at the time of BMT may play an important role in the latency of bcr-abl positivity after BMT.

Original languageEnglish
Pages (from-to)1089-1093
Number of pages5
JournalBlood
Volume81
Issue number4
Publication statusPublished - Feb 15 1993
Externally publishedYes

Fingerprint

Transplants
Polymerase chain reaction
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone
Bone Marrow Transplantation
Bone Marrow
Recurrence
Polymerase Chain Reaction
Homologous Transplantation
Tumors
Tumor Burden
Leukocyte Count
Cytogenetics

ASJC Scopus subject areas

  • Hematology

Cite this

Miyamura, K., Tahara, T., Tanimoto, M., Morishita, Y., Kawashima, K., Morishima, Y., ... Mizutani, S. (1993). Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: A study of 64 patients. Blood, 81(4), 1089-1093.

Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse : A study of 64 patients. / Miyamura, Koichi; Tahara, Tohru; Tanimoto, Mitsune; Morishita, Yoshihisa; Kawashima, Kouhei; Morishima, Yasuo; Saito, Hidehiko; Tsuzuki, Shinobu; Takeyama, Kunihiko; Kodera, Yoshihisa; Matsuyama, Kohji; Hirabayashi, Noriyuki; Yamada, Hironori; Naito, Kazuyuki; Imai, Kuniyuki; Sakamaki, Hisashi; Asai, Osamu; Mizutani, Shuki.

In: Blood, Vol. 81, No. 4, 15.02.1993, p. 1089-1093.

Research output: Contribution to journalArticle

Miyamura, K, Tahara, T, Tanimoto, M, Morishita, Y, Kawashima, K, Morishima, Y, Saito, H, Tsuzuki, S, Takeyama, K, Kodera, Y, Matsuyama, K, Hirabayashi, N, Yamada, H, Naito, K, Imai, K, Sakamaki, H, Asai, O & Mizutani, S 1993, 'Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: A study of 64 patients', Blood, vol. 81, no. 4, pp. 1089-1093.
Miyamura, Koichi ; Tahara, Tohru ; Tanimoto, Mitsune ; Morishita, Yoshihisa ; Kawashima, Kouhei ; Morishima, Yasuo ; Saito, Hidehiko ; Tsuzuki, Shinobu ; Takeyama, Kunihiko ; Kodera, Yoshihisa ; Matsuyama, Kohji ; Hirabayashi, Noriyuki ; Yamada, Hironori ; Naito, Kazuyuki ; Imai, Kuniyuki ; Sakamaki, Hisashi ; Asai, Osamu ; Mizutani, Shuki. / Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse : A study of 64 patients. In: Blood. 1993 ; Vol. 81, No. 4. pp. 1089-1093.
@article{3ba86f8540884aabb111f400f0bc9a7e,
title = "Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: A study of 64 patients",
abstract = "We report here the results of polymerase chain reaction (PCR) for bcr-abl transcript and clinical details derived from 64 chronic myelogenous leukemia (CML) patients after allogeneic bone marrow transplantation (BMT). A total of 139 samples (2 to 220 weeks after BMT) were analyzed and bcr-abl transcript was detected in 99 samples from 52 patients. Patients were defined as bcr-abl early negative (EN) if they had ≥1 negative PCR result ≤1 year post-BMT (n = 13), and bcr-abl late positive (LP) if they had ≥1 positive PCR result ≥1 year post-BMT (n = 21). Among LP patients, only two patients had hematologic/cytogenetic (clinical) relapse. Another 19 LP patients remained in clinical remission 7 to 130 weeks after positive analysis for bcr-abl transcript, including 5 patients who had persistent bcr-abl transcript detectable even 2 years after BMT. To estimate the relationship between clinical data and residual bcr-abl transcript, EN patients are compared with LP patients. However, no clinical data studied were significantly associated with the persistent PCR positivity. If only patients in chronic phase are compared, the t-test showed significant correlation between leukocyte count just before BMT and sustained bcr-abl transcript (P <.05). These results suggest that PCR positivity is frequently observed in CML patients who sustain clinical remission after BMT, without being predictive of imminent clinical relapse. Tumor burden at the time of BMT may play an important role in the latency of bcr-abl positivity after BMT.",
author = "Koichi Miyamura and Tohru Tahara and Mitsune Tanimoto and Yoshihisa Morishita and Kouhei Kawashima and Yasuo Morishima and Hidehiko Saito and Shinobu Tsuzuki and Kunihiko Takeyama and Yoshihisa Kodera and Kohji Matsuyama and Noriyuki Hirabayashi and Hironori Yamada and Kazuyuki Naito and Kuniyuki Imai and Hisashi Sakamaki and Osamu Asai and Shuki Mizutani",
year = "1993",
month = "2",
day = "15",
language = "English",
volume = "81",
pages = "1089--1093",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse

T2 - A study of 64 patients

AU - Miyamura, Koichi

AU - Tahara, Tohru

AU - Tanimoto, Mitsune

AU - Morishita, Yoshihisa

AU - Kawashima, Kouhei

AU - Morishima, Yasuo

AU - Saito, Hidehiko

AU - Tsuzuki, Shinobu

AU - Takeyama, Kunihiko

AU - Kodera, Yoshihisa

AU - Matsuyama, Kohji

AU - Hirabayashi, Noriyuki

AU - Yamada, Hironori

AU - Naito, Kazuyuki

AU - Imai, Kuniyuki

AU - Sakamaki, Hisashi

AU - Asai, Osamu

AU - Mizutani, Shuki

PY - 1993/2/15

Y1 - 1993/2/15

N2 - We report here the results of polymerase chain reaction (PCR) for bcr-abl transcript and clinical details derived from 64 chronic myelogenous leukemia (CML) patients after allogeneic bone marrow transplantation (BMT). A total of 139 samples (2 to 220 weeks after BMT) were analyzed and bcr-abl transcript was detected in 99 samples from 52 patients. Patients were defined as bcr-abl early negative (EN) if they had ≥1 negative PCR result ≤1 year post-BMT (n = 13), and bcr-abl late positive (LP) if they had ≥1 positive PCR result ≥1 year post-BMT (n = 21). Among LP patients, only two patients had hematologic/cytogenetic (clinical) relapse. Another 19 LP patients remained in clinical remission 7 to 130 weeks after positive analysis for bcr-abl transcript, including 5 patients who had persistent bcr-abl transcript detectable even 2 years after BMT. To estimate the relationship between clinical data and residual bcr-abl transcript, EN patients are compared with LP patients. However, no clinical data studied were significantly associated with the persistent PCR positivity. If only patients in chronic phase are compared, the t-test showed significant correlation between leukocyte count just before BMT and sustained bcr-abl transcript (P <.05). These results suggest that PCR positivity is frequently observed in CML patients who sustain clinical remission after BMT, without being predictive of imminent clinical relapse. Tumor burden at the time of BMT may play an important role in the latency of bcr-abl positivity after BMT.

AB - We report here the results of polymerase chain reaction (PCR) for bcr-abl transcript and clinical details derived from 64 chronic myelogenous leukemia (CML) patients after allogeneic bone marrow transplantation (BMT). A total of 139 samples (2 to 220 weeks after BMT) were analyzed and bcr-abl transcript was detected in 99 samples from 52 patients. Patients were defined as bcr-abl early negative (EN) if they had ≥1 negative PCR result ≤1 year post-BMT (n = 13), and bcr-abl late positive (LP) if they had ≥1 positive PCR result ≥1 year post-BMT (n = 21). Among LP patients, only two patients had hematologic/cytogenetic (clinical) relapse. Another 19 LP patients remained in clinical remission 7 to 130 weeks after positive analysis for bcr-abl transcript, including 5 patients who had persistent bcr-abl transcript detectable even 2 years after BMT. To estimate the relationship between clinical data and residual bcr-abl transcript, EN patients are compared with LP patients. However, no clinical data studied were significantly associated with the persistent PCR positivity. If only patients in chronic phase are compared, the t-test showed significant correlation between leukocyte count just before BMT and sustained bcr-abl transcript (P <.05). These results suggest that PCR positivity is frequently observed in CML patients who sustain clinical remission after BMT, without being predictive of imminent clinical relapse. Tumor burden at the time of BMT may play an important role in the latency of bcr-abl positivity after BMT.

UR - http://www.scopus.com/inward/record.url?scp=0027465939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027465939&partnerID=8YFLogxK

M3 - Article

VL - 81

SP - 1089

EP - 1093

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -